Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activity

Annals of Oncology

Volumn 10, Issue 12, 1999, Pages 1525-1527

  Byrd, J C ^a,b,c   White, C A ^d   Link, B ^e   Lucas, M S ^a,b   Velasquez, W S ^f   Rosenberg, J ^d   Grillo Lopez A J ^d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BIOGEN   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Lymphoma; Monoclonal antibodies; Non Hodgkin's; Rituxan; Rituximab; Waldenstrom's macroglobulinemia anti CD20

Indexed keywords

FLUDARABINE; IMMUNOGLOBULIN M; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PARAPROTEINEMIA; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 0033395792     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008350208019     Document Type: Article

References (12)

1. Dimopoulos MA, Alexanian R. Waldenstrom's macroglobulinemia. Blood 1994; 83: 1452-9.
2. Waldenstrom J. Incipient myclomatosis or 'essential' hyperglobulinemia with fibrinogenopenia a new syndrome? Acta Med Scand 1944; 117: 216-22.
3. Armitage JO. Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J Clin Oncol 1998; 16: 2780-95.
4. Kyle RA, Greipp PR, Gertz MA et al. Waldenstrom's macroglobulinemia: A prospective study comparing dialy versus intermittent oral chlorambucil. Blood 1998; 92: 279b (Abstr 4204).
5. Dimopoulos MA, Kantargian H, Estey E et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195-8.
6. Dimopoulos M, O'Brien S, Kantarjian H et al. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am J Med 1993; 95: 49-52.
7. Leblond V, Ben-Othman T. Deconinck E et al. Activity of fludarabine in previously treated Waldenstrom's macroglobulinemia: A report of 71 cases, J Clin Oncol 1998; 16: 2060-4.
8. Byrd JC, Hargis JB, Kester KE et al. Opportunistic infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: A role for pneumocystis carinii pneumonia propylaxis. Am J Hematol 1995; 49: 135-42.
9. Maloney DJ, Grillo-López AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
10. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
11. Davis TA, White CA, Grillo-López AJ et al. Rituximab: First report of a phase II trial in NHL patients with bulky disease. Blood 1998; 92: 414a (Abstr 1711).
12. Byrd JC, Waselenko JK, Maneatis T et al. Association of rapid tumor lysis in patients with lymphoproliferative disorders possessing a high number of circulating peripheral blood tumor cells. J Clin Oncol 1999; 17: 791-5.